z-logo
open-access-imgOpen Access
Role of FABP3 as Biomarker in Alzheimer's Disease and Synucleinopathies
Author(s) -
Federica Nicoletta Sepe,
Davide Chiasserini,
Lucilla Parnetti
Publication year - 2018
Publication title -
future neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 32
eISSN - 1748-6971
pISSN - 1479-6708
DOI - 10.2217/fnl-2018-0003
Subject(s) - synucleinopathies , neurodegeneration , biomarker , dementia with lewy bodies , dementia , biology , fatty acid binding protein , disease , neuroscience , alzheimer's disease , synuclein , pathogenesis , biochemistry , alpha synuclein , microbiology and biotechnology , parkinson's disease , medicine , pathology , gene , immunology
Lipids are fundamental components of brain cells as they are involved in several essential processes like remodeling of plasma membrane, synaptic function and receptor–ligand interactions. Systemic and brain alterations in lipid metabolism have been linked to the pathogenesis of neurodegenerative disorders like dementia and parkinsonisms. Intracellular transport of lipids is regulated by fatty acid-binding proteins. Recently, a member of this family, the fatty acid-binding protein 3 has been proposed as a potential biomarker across a range of neurodegenerative diseases, including Alzheimer's disease and dementia with Lewy bodies. In this special report, we describe recent progresses in characterizing the role of fatty acid-binding protein 3 in neurodegeneration and its putative role as biomarker measurable in biological fluids.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom